A number of new disease-modifying therapies have recently been developed and approved for use in adult-onset multiple sclerosis. However, few treatment options are approved for patients with paediatric-onset multiple sclerosis. There are an increasing number of clinical trials evaluating the efficacy and safety of disease-modifying therapies in children and teens living with multiple sclerosis. Clinical trials are difficult to complete in rare diseases like paediatric-onset multiple sclerosis; however, it is critical to assess safety and monitoring in this vulnerable population by applying robust research methodology to randomized controlled clinical trials. Longer-term extension analyses are also needed to better evaluate the efficacy, dosing and long-term safety of adult disease-modifying therapy for use in paediatric-onset multiple sclerosis. Future research should focus on defining optimal first-line disease-modifying therapy in paediatric-onset multiple sclerosis as related to both efficacy and safety, improving recruitment and completion rates of clinical trials, identifying relevant biomarkers of disease activity, analysing outcome measures related to treatment response and assessing long-term safety for this unique population living with a chronic disease.

Paediatric-onset multiple sclerosis (POMS) is the symptom onset and diagnosis of multiple sclerosis (MS) before the age of 18. Diagnostic criteria were revised by the International Pediatric MS Study Group in 2013. Compared to patients with adult-onset MS (AOMS), young patients are less likely to develop primary or secondary progressive MS and more likely to follow a relapsing–remitting course. Although early relapses in patients with POMS tend to be more highly inflammatory and more frequent, children seem to demonstrate more resiliency, recovering more quickly and effectively from each attack. However, there is growing evidence that patients with POMS still require early treatment with a highly effective disease-modifying therapy (DMT) to help prevent significant long-term disability. Over the past decade, there has been a rapid development of new DMTs for AOMS, including four that have been newly US Food and Drug Administration (FDA)-approved in the past 2 years (Table 1). These include ofatumumab and several new S1P receptor modulators (Table 1). Ofatumumab is a B-cell depleting therapy similar to rituximab and ocrelizumab but is given by monthly subcutaneous injection following an induction of three weekly injections. After observation of the first dose to ensure safety, patients can then dose themselves at home without the need to travel to an infusion centre. The new S1P modulators were developed as alternatives to fingolimod, with the goal of improved safety such as a lack of stringent first-dose cardiac monitoring with some of the new products. However, the short- and long-term safety, dosing and effectiveness of most AOMS DMTs in the POMS population requires further clarification. New clinical trials exploring DMT use in POMS continue to emerge.

From 2006 through 2020, a total of three treatment trials analysing DMT use in POMS have been published. These include interferon β-1a, fingolimod and teriflunomide. Interferon β-1a is a first-generation injectable interferon requiring frequent dosing, fingolimod is a once-a-day oral sphingosine 1-phosphate (S1P) receptor modulator and teriflunomide is a once-a-day oral pyrimidine synthesis inhibitor.

The first treatment trial examined interferon β-1a use in 16 children with POMS, demonstrating overall stable median Expanded Disability Status Score and magnetic resonance imaging (MRI) activity in three patients, with worsening in six patients. It was well-tolerated, with side effects including flu-like symptoms, isolated myalgias and injection-site reactions. Treatment was not interrupted in any cases due to adverse events. Compared with interferon β-1a, the fingolimod trial demonstrated a relative decrease of 88% in adjusted annualized relapse rate, 53% reduction in annualized rate of new or newly enlarged T2 lesions and a higher rate of serious adverse events. A 2-year follow-up analysis showed sustained reduction in MRI activity and annualized rate of brain atrophy. continued control of disease activity and less disability progression. The third treatment trial compared teriflunomide against placebo in 166 patients with POMS,
Table 1: Approved adult-onset multiple sclerosis therapies from 2020 to present^a

| Drug               | Brand name, approval year | Mechanism of action                                                                 | Maintenance dosing                      |
|--------------------|----------------------------|-------------------------------------------------------------------------------------|----------------------------------------|
| **INJECTABLES**    |                            |                                                                                     |                                        |
| Ofatumumab         | Kesimpta™, 2020^a          | Monoclonal antibody directed against the CD20 antigen on the surface of B lymphocytes, causing temporary depletion of B cells | 20 mg subcutaneously monthly           |
| **ORALS**          |                            |                                                                                     |                                        |
| Ozanimod           | Zeposia™, 2020^a           | Decreases CNS inflammation by blocking entry of activated T cells from lymph nodes to blood stream | 0.92 mg po daily                      |
| Ponesimod          | Ponvory™, 2021^b           | Decreases CNS inflammation by blocking entry of activated T cells from lymph nodes to blood stream | 20 mg po daily                        |
| Monomethyl Fumarate| Bafiertam™, 2020^b         | May decrease inflammation by improving cellular response to oxidative stress by activating nuclear factor-like 2 pathway | 190 mg po bid                         |

*bid = twice daily; CNS = central nervous system; po = by mouth.

Most POMS DMT data comes from two retrospective analysis papers published in 2018 and 2020.6-7 For both analyses, clinical data was collected prospectively from a network of 12 Pediatric MS Centers throughout the USA and Canada. The 2020 retrospective paper looked at a total of 741 paediatric patients with MS and clinically isolated syndrome between 2011 and 2019 using propensity scores.8 The most significant finding was that early initiation of a highly effective DMT (as defined in the adult literature) led to more favourable outcomes compared to injectables.9 Furthermore, the DMT safety profiles were overall similar to those observed in adult trials.6-8

The purpose of this review is to provide updates on the most recent research investigating DMT use in POMS.

**Methods**

This narrative review includes a study of both publications and clinical trials published after 2020. For recent POMS DMT trials, a search was conducted using ClinicalTrials.gov by entering “pediatric multiple sclerosis” under [Condition or disease]. The following filters were subsequently checked under [Recruitment Status]: “recruiting”, “active not recruiting” and “completed”. To restrict the results to only recent trials, all “completed” studies prior to 2020 were excluded. All “active” studies, even those prior to 2020, were included, as some of the follow-up analyses have not yet been completed. Additional filters applied included “child (birth-17)” for [age] and “interventional” for [study type]. To restrict the results to include only drug treatment trials, only those listing the name of a specific MS DMT listed under the “intervention” column were included.

For recent publications, a search was conducted using PubMed by entering the following keywords under [Title/Abstract]: “pediatric multiple sclerosis” and the names of all available MS DMTs. To restrict the results to include only the most recent articles, date range filters were set to between “2020/01/01” and “2021/12/31”. All article types were subsequently included in the results.

**Results**

The POMS clinical treatment trials search yielded nine investigations (Table 2) and the publications search yielded 10 publications (Table 3). Of the nine new clinical treatment trials, there were four phase III investigations initiated after 2019 (Table 2). The first, comparing dimethyl fumarate (DMF) with peginterferon β-1a, aims to show that DMF is effective and safe enough to warrant its use as a first-line therapy over first-generation injectables (Study to evaluate the efficacy and safety of dimethyl fumarate [Tecfidera] and peginterferon beta-1a [Plegridy] for the treatment of relapsing-remitting multiple sclerosis in pediatric participants; ClinicalTrials.gov identifier: NCT03870763).12 The second, comparing ocrelizumab with fingolimod, was likely designed for two major reasons: to demonstrate that ocrelizumab is at least as effective as fingolimod and therefore warrants FDA approval in POMS, and to investigate whether ocrelizumab is more effective than fingolimod and thus should serve as the preferred first-line option for patients with POMS (A study to evaluate safety and efficacy of ocrelizumab in comparison with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis [Operetta 2]; ClinicalTrials.gov identifier: NCT021523703).13 The third trial, which compares ofatumumab and siponimod to fingolimod, also likely aims to clarify the optimal first-line DMT in POMS (Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis [NEOS]; ClinicalTrials.gov identifier: NCT04926818).14 Siponimod is a newer once-a-day oral S1P modulator alternative to fingolimod.15 The fourth trial compares peginterferon β-1a with the active comparator interferon β-1a to evaluate its effectiveness and safety in POMS (A study to evaluate the safety, tolerability, and efficacy of BIIB017 [peginterferon beta-1a] in pediatric participants for the treatment of relapsing-remitting multiple sclerosis; ClinicalTrials.gov identifier: NCT03958877).16

Our comprehensive literature search yielded 10 recent manuscripts on DMT use in POMS, of which there were three trial results papers and one review article (Table 3). The remainder were case reports and case series. In the first trial article, Arnold et al. reported on the predefined MRI outcomes from the trial, demonstrating that fingolimod significantly reduced MRI activity and annualized rate of brain atrophy compared to interferon β-1a (Safety and efficacy of fingolimod in pediatric patients with multiple sclerosis [PARADIGMS]; ClinicalTrials.gov identifier: NCT01892722).17-19 In the second, Atoughani et al. published the results of a 96-week extension to the phase II DMF trial for patients 13 to 17 years of age with relapsing-
| Study, NCT identifier          | Recruitment status | Year          | Enrollment | Study phase | Study design                                                                 | Primary objective                                      | Secondary objectives                                                                 |
|-------------------------------|--------------------|---------------|------------|-------------|------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------|
| Efficacy, safety and pharmacokinetics of teriflunomide in pediatric patients with relapsing forms of MS (TERIKIDS) (NCT02201108) | Completed          | 2014–2021     | Actual: 166 | Phase III | Teriflunomide in randomized, placebo-controlled, followed by open-label extension period; Parallel assignment; Quadruple blinding | Time to first relapse                                    | Safety and tolerability; Pharmacokinetics; Effect on disease progression               |
| Safety and efficacy of fingolimod in pediatric patients with MS (NCT01892722) | Recruiting (Extension Phase) | 2013–2028     | Goal: 220  | Phase III | Fingolimod in open-label extension phase                                     | Frequency of relapses in patients treated for up to 24 months | Pharmacokinetics; Time to first relapse; Effect on MRI                                |
| Evaluate the safety, tolerability, and efficacy of peginterferon β-1a in pediatric patients with RRMS (NCT03958877) | Recruiting         | 2019–2029     | Goal: 142  | Phase III | Peginterferon β-1a in randomized, active control to interferon β-1a, followed by open-label extension period; Parallel assignment; Open label | ARR at Week 96 Percentage of participants with AEs, serious AEs, and AEs leading to study treatment discontinuation | Safety, tolerability and descriptive efficacy; Pharmacokinetics; Long-term safety (open-label extension) |
| Safety, tolerability, pharmacokinetics and pharmacodynamic effects of ocrelizumab in pediatric patients with RRMS (NCT04075266) | Recruiting         | 2020–2027     | Goal: 36   | Phase II  | Ocrelizumab in parallel assignment; Open label                               | Serum concentration of ocrelizumab, Levels of CD19+ B-cell count in blood | AEs; Level of circulating WBCs; Effect on certain developmental milestones including height, growth velocity and Tanner staging; ADAs; Antibody titers against vaccines; Non-MS CNS pathology on Brain MRI; Serum immunoglobulins |
| Efficacy and safety of ofatumumab and siponimod compared with fingolimod in pediatric patients with MS (NEOS) (NCT04992618) | Recruiting         | 2021–2029     | Goal: 180  | Phase III | Ofatumumab in randomized, active control to interferon β-1a, followed by open-label extension period; Parallel assignment; Open label | ARR as compared with interferon-β 1a; Annualized T2 lesion rate; Pharmacokinetics of ofatumumab and Siponimod; Percentage of participants with ADAs; AEs or serious AEs (extension phase) |                                                        |
| Safety and efficacy of ocrelizumab in comparison with fingolimod in pediatric patients with RRMS (Operetta 2) (NCT03123703) | Recruiting         | 2022–2025     | Goal: 233  | Phase III | Ocrelizumab in randomized double-dummy to fingolimod; Parallel assignment; Quadruple blinding | ARR | AEs; Effect on disease progression on MRI; ADAs at baseline and during study |
remitting multiple sclerosis (RRMS) (Efficacy and safety of BG00012 in pediatric patients with RRMS [CONNECT], ClinicalTrials.gov identifier: NCT02283853), Extension study of BG00012 in pediatric subjects with relapsing remitting multiple sclerosis [FOCUS], ClinicalTrials.gov identifier: NCT02555215). 25,28,36,37 DMF is a twice daily oral activator of the nuclear factor (erythroid-derived 2)-like pathway. 38 Of the patients with POMS enrolled, 37 of the original 57 patients assigned to placebo completing the double-blind treatment period early due to either high MRI activity or related disorders in the hopes of establishing a more standardized protocol. 26 The authors began by mentioning the phase I study of ocrelizumab, which is now transitioning into phase III (Table 2). They then summarized rituximab use in AOMS and presented the available retrospective data published on rituximab use in several paediatric.

Table 2: Continued

| Study, NCT identifier | Recruitment status | Year | Enrolment | Study phase | Study design | Primary objective | Secondary objectives |
|-----------------------|--------------------|------|-----------|-------------|--------------|-------------------|---------------------|
| Efficacy and safety of BG00012 in pediatric patients with RRMS (CONNECT) (NCT02283853) | Active, not recruiting | 2014–2025 | Actual: 156 | Phase III | Dimethyl fumarate in randomized, active control to interferon beta type 1a, followed by open-label extension period; Parallel assignment; Open label | Patients without new/newly enlarging T2 hyperintense lesions on MRI at Week 96; AEs, serious AEs and discontinuation due to AEs (extension phase) | Number of new/newly enlarging T2 hyperintense lesions at weeks 24 and 96; Proportion of patients free of new/enlarging T2 hyperintense lesions at weeks 24 and 48; Proportion of patients free of new brain MRI activity at weeks 24, 48 and 96; Time to first relapse; Proportion of patients who experience no relapse; ARR; AEs, serious AEs, and discontinuation due to AEs up to week 96; QoL measures (fatigue, Peds QL, EDSS); Vital signs, electrocardiograms and monitoring clinical laboratory data |
| Evaluate the efficacy, safety and tolerability of alemtuzumab in pediatric patients with RRMS with disease activity on prior DMT (LemKids) (NCT03368644) | Active, not recruiting | 2017–2025 | Goal: 50 | Phase III | Alemtuzumab in single-group assignment; open label | Number of new or enlarging T2 lesions | Change in EDSS; ARR; Assessment of cognition test scores; Paediatric QoL measures; Pharmacokinetics; Pharmacodynamics; ADA formation; AEs |
| Evaluate the efficacy and safety of dimethyl fumarate and peginterferon β-1a for the treatment of RRMS in pediatric patients (NCT03870763) | Active, not recruiting | 2019–2021 | Actual: 11 | Phase III | Dimethyl fumarate in randomized, placebo-controlled; Parallel assignment; Quadruple blinding | Time to first relapse | ARR; AEs or serious AEs; Effect on MRI |

ADA = anti-drug antibody; AE = adverse event; ARR = annualized relapse rate; CNS = central nervous system; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; IV = intravenous; MS = multiple sclerosis; MRI = magnetic resonance imaging; QoL = quality of life; RRMS = relapsing–remitting multiple sclerosis; WBC = white blood cell.
neuroinflammatory diseases. The 2013 International Pediatric MS Study Group’s position on rituximab is that it has significant potential benefit but requires further investigation to establish a standardized therapeutic protocol. The review authors go on to propose a practical framework for rituximab use in POMS, giving particular attention to dosing, frequency and monitoring parameters. At present, rituximab has not been formally approved for use in POMS by the FDA or the Canadian Health Products and Food Branch. Of note, it has also not been FDA-approved for AOMS. Therefore, the authors emphasized the need for additional short- and long-term data on rituximab use in POMS. They also raised specific concerns surrounding the increased infection risks in light of the coronavirus disease 2019 (COVID-19) pandemic.

Our search yielded a number of new case studies. In a case series of three patients, Merô et al. explained how poor outcomes observed in almost 45% of patients with POMS taking first-generation injectables prompted the PARADIGMS and CONNECT trials to examine higher-eficacy options more closely. They then presented three active patients with RRMS successfully treated with natalizumab. A paper by Hunt and Trabousee described two patients with POMS treated with alemtuzumab with favourable responses. Multiple additional case reports supported the results of the PARADIGMS trial, showing that fingolimod was well-tolerated and effective as first- or second-choice therapy in POMS. This included a report of three patients by Fenili et al. with radiologic disease stability 11–17 months after initiation of fingolimod. Furthermore, two separate case reports by Immovilli et al. and Amidei et al. each presented a patient with POMS who switched to fingolimod following failed interferon β-1a therapy, resulting in disease stability. Finally, a case report by Gontika et al. described seven patients, three of whom were treatment-naïve and received fingolimod. Their level of disease activity following treatment suggested that response to fingolimod may be at least partially dependent on age and previous immunomodulatory therapy.

## Discussion

Based on our above comprehensive review of the literature, the most recent research provides growing support for starting patients newly diagnosed with POMS on highly effective DMTs as early as possible. The initiation of four new clinical POMS DMT trials will hopefully provide further justification for this. The results may also help facilitate payor approvals and instil providers with more confidence to prescribe newer DMTs to patients with POMS. One unanswered question is the use of newer DMTs in patients less than 10 years of age. Since this cohort represents such a small fraction of the overall MS population, post-hoc

### Table 3: Paediatric-onset multiple sclerosis therapy publications from 2020 to the present

| Title                                                                 | Year | Type             | Treatment     | Participants | Conclusions                                                                 |
|----------------------------------------------------------------------|------|-----------------|---------------|--------------|-----------------------------------------------------------------------------|
| Effect of fingolimod on MRI outcomes in patients with paediatric-onset MS: results from the phase III PARADIGMS study    | 2020 | Phase III clinical trial | Fingolimod   | 215          | Fingolimod significantly reduced MRI activity and annualized rate of brain atrophy for up to 2 years versus interferon β-1a in paediatric-onset MS |
| Delayed-release dimethyl fumarate safety and efficacy in paediatric patients with RRMS                              | 2021 | Phase II clinical trial | Dimethyl fumarate | 17          | Long-term safety profile in paediatric patients seems consistent with that seen in adults |
| Safety and efficacy of teriflunomide in pediatric-onset MS (TERIKIDS): a multicentre, double-blind, phase II, randomized, placebo-controlled trial | 2021 | Phase III clinical trial | Teriflunomide | 166         | No significant difference in time to first relapse compared to placebo, reduced number of new T2 lesions. No new or unexpected safety concerns |
| Short-term outcomes of pediatric-onset MS patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic | 2020 | Case report     | Alemtuzumab   | 2           | 2 patients with paediatric-onset MS experienced improvement in EDSS with alemtuzumab without serious infusion reactions, infections or definite relapses |
| Fingolimod in pediatric MS: three case reports                      | 2021 | Case report     | Fingolimod   | 3           | Fingolimod as first- or second-choice therapy was well-tolerated, with radiologic stability in 3 patients over a range of 11–17 months of treatment |
| Two-year follow-up during fingolimod treatment in a pediatric-onset MS patient still active on first-line treatment | 2021 | Case report     | Fingolimod   | 1           | Treatment with fingolimod was effective following treatment with interferon β-1a |
| Efficacy of fingolimod after switching from interferon β-1a in an adolescent with MS: case report                  | 2021 | Case report     | Fingolimod   | 1           | Fingolimod was well-tolerated in patients with paediatric-onset MS following interferon β-1a, with clinical and radiologic stability after 2 years |
| Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset MS: focus on immunological data | 2021 | Case report     | Fingolimod   | 7           | The response of fingolimod in paediatric-onset MS seems to be partially dependent on age and previous immunomodulatory therapy |
| Effective therapy in highly active pediatric-onset multiple sclerosis | 2021 | Case Report     | Natalizumab  | 3           | Natalizumab was effective and well-tolerated in paediatric RRMS patients |
| Rituximab in patients with pediatric-onset MS and other demyelinating disorders of the CNS: Practical considerations | 2021 | Review          | Rituximab   | Not applicable | Additional studies are needed to aid in standardization of rituximab as possible DMT for patients with paediatric-onset MS |

CNS = central nervous system; DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; MRI = magnetic resonance imaging; MS = multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis.
Table 4: International paediatric multiple sclerosis study group recommendations for clinical trials in paediatric-onset multiple sclerosis

| Regulatory recommendations | Trial design recommendations | Safety monitoring recommendations |
|----------------------------|-----------------------------|----------------------------------|
| Different world regions’ regulatory agencies should harmonize clinical trial design requirements for paediatric MS therapeutic trials of immunomodulating agents | Placebo-controlled trials of immunomodulatory agents proven effective in adult patients with MS are inappropriate in paediatric patients with MS | Open-label extension studies should be mandated for all clinical trials in paediatric-onset MS populations |
| No more than one phase III clinical trial should be performed for the same pharmacologic agent | Future phase III registration trials in adults should consider enrolment of teenager patients with MS | Open-label studies or registries should be designed to monitor safety in patients ages 12 and under |
| In vitro and animal studies related to the use of a drug in paediatric patients should be performed early on to avoid postponing appropriate testing in human paediatric patients | Open-label study, including PK/PD and safety endpoints, should be considered as sufficient for registration in paediatric-onset MS for agents that have been well-studied in adults and have demonstrated through PD and statistical modelling extrapolated predictions for the paediatric age range that would support efficacy |  |
| PK and PD paediatric studies should be completed for all new agents to allow identification of appropriate paediatric dosing | A short, controlled trial with an MRI primary endpoint is recommended rather than a clinical endpoint in the case that an open-label study (including PK, PD and safety endpoints) is deemed insufficient for registration in paediatric-onset MS; provided that the pivotal adult study for the same agent demonstrated a strong relationship between clinical efficacy and MRI endpoints |  |
| | In randomized controlled trials of immunomodulating agents, the control drug may be fingolimod, or other agents commonly used in paediatric-onset MS |  |
| | For agents for which a phase III trial with a clinical primary endpoint is mandated by regulatory agencies, time to event analyses should be favoured over ARR as this allows for prompter switch to more effective therapies |  |
| | For add-on trials, the new agent could be compared to placebo, provided that immunomodulatory therapies are maintained |  |

ARR = annualized relapse rate; MRI = magnetic resonance imaging; MS = multiple sclerosis; PD = pharmacodynamics; PK = pharmacokinetics.

analyses often lack sufficient power and introduce additional biases. Moreover, this particularly vulnerable population presents additional ethical challenges, and a lack of standardized weight-based dosing guidelines makes prescribing newer DMTs to such patients challenging for providers. There are on-going trials looking at the pharmacodynamics of DMT use based on various weights and ages in POMS.41,42 It is also important to learn from other subspecialties in this regard, as rituximab is often the only medication considered in very young patients with POMS, with dosing regimens largely based on experience with paediatric rheumatological disorders.43

Recent legislation in both the USA and Europe has mandated a good faith effort for pharmaceutical companies to complete POMS trials.44 Clinical trials in POMS are difficult to complete for a number of reasons, including patient recruitment and the rarity of the disease. For example, only 166 patients with POMS were enrolled in the TERIKIDS trial over a 5-year period at 57 different centres across 22 countries, in comparison to its adult trial counterpart, which enrolled 1088 patients over 4 years at 127 different sites across 21 countries.45,46 As discussed in a commentary by Sormani and Waubant, the statistical significance for the primary endpoint of the TERIKIDS trials was not reached despite the same effect being observed in adult teriflunomide trials for reduction in new MRI lesions and ARR. This was likely a result of the study being underpowered due to small trial size.47 Nonetheless, the European Union deemed the results worthy enough to approve teriflunomide for use in POMS. The FDA, however, did not. Unless new strategies are applied to paediatric drug trials, underpowered studies will likely continue to hinder efforts to gain FDA approval of new DMTs to treat POMS.

Other research barriers include the global COVID-19 pandemic, lack of consensus regarding primary outcome and quality of life measures, and ethical concerns. Additional POMS trials are necessary to evaluate the pharmacokinetics, safety and efficacy required to gain regulatory approval and to enhance medication access and long-term outcomes for patients with POMS. Unique biomarkers of POMS may help to assist in the precision of POMS clinical trials. For example, optical coherence tomography and neurofilament light chain are being evaluated as possible means to clarify the level of disease activity in POMS.48-49 A global summit was also held in 2019 to formulate 13 clear mandates to assist in designing, recruiting and completing POMS clinical trials (Table 4).47

Conclusions

The number of new highly effective DMT options for adult MS that have emerged over the past decade is impressive. When designing clinical MS trials, there is a general sense that adult trials must always be performed prior to the inclusion of paediatric patients, often due to recruitment, safety and ethical challenges.40 This can create significant delays in gaining FDA approval of adult drugs for use in the paediatric population. Fingolimod, for example, was approved for use in AOMS in 2010, but not until 2018 for POMS.41 In light of the growing evidence supporting the safety and effectiveness of adult DMTs in paediatric patients, it is worth reconsidering whether the exclusion of paediatric patients from adult research trials remains in the best interest of patients.
can avoid the significant delays that often occur in the completion of studies and extensions.

18. Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapies in pediatric multiple sclerosis in the US. Mult Scler Relat Disord. 2020;41:102051.

19. ClinicalTrials.gov. Efficacy, safety and pharmacokinetics of oralesumab in patients with multiple sclerosis. Available at: https://clinicaltrials.gov/ct2/show/NCT04075967 (accessed 24 January 2022).

20. ClinicalTrials.gov. Safety and efficacy of fingolimod in pediatric patients with multiple sclerosis. ClinicalTrials.gov Identifier: NCT01997272. Available at: https://clinicaltrials.gov/ct2/show/NCT01997272 (accessed 24 January 2022).

21. ClinicalTrials.gov. Safety, tolerability, and efficacy of safety of fatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis. ClinicalTrials.gov Identifier: NCT01492618. Available at: https://clinicaltrials.gov/ct2/show/NCT01492618 (accessed 24 January 2022).

22. ClinicalTrials.gov. A study to evaluate safety and efficacy of oralesumab in comparison with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis (Operetta 2). ClinicalTrials.gov Identifier: NCT01513703. Available at: https://clinicaltrials.gov/ct2/show/NCT01521303 (accessed 24 January 2022).

23. ClinicalTrials.gov. A Phase 3 efficacy and safety study of BG00012 in pediatric subjects with relapsing-remitting multiple sclerosis (CONNECT). ClinicalTrials.gov Identifier: NCT02838663. Available at: https://clinicaltrials.gov/ct2/show/NCT02838663 (accessed 24 January 2022).

24. ClinicalTrials.gov. A study to evaluate efficacy, safety, and tolerability of alemtuzumab in pediatric patients with RMS with disease activity on prior DMT (Leukids). ClinicalTrials.gov Identifier: NCT03586646. Available at: https://clinicaltrials.gov/ct2/show/NCT03586646 (accessed 24 January 2022).

25. ClinicalTrials.gov. Study to evaluate the efficacy and safety of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Pegasys) for the treatment of relapsing-remitting multiple sclerosis in pediatric patients. ClinicalTrials.gov Identifier: NCT03870763. Available at: https://clinicaltrials.gov/ct2/show/NCT03870763 (accessed 24 January 2022).

26. Aruojohi R, Huppi P, Mazurek-Fiedziukowska M, et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. Front Neurol. 2021;11:608418.

27. Hunt DJ, Trabulsei A, Short-term outcomes of systemic multiple sclerosis patients treated with alemtuzumab at a Canadian University. J Neurol Sci. 2022;435:106216.

28. Alroughani R, Baskin R, Gold R, Tehrani-Shahrokh M, et al. Clinical Trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IMPPSG. Neurology. 2019;92:1038-49.

29. Lagier F, Hirschfeld S, Kimblum JM. Challenges in clinical trials for children and young people. Arch Dis Child. 2021;106:521-5.

30. U.S. Food and Drug Administration. FDA-Approved Drugs. Available at: www.accessdata.fda.gov/-drugsatfda_docs/label/2020/209899s000lbl.pdf (accessed 14 May 2022).

31. Aruojohi R, Baskin R, Gold R, Tehrani-Shahrokh M, et al. Clinical Trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IMPPSG. Neurology. 2019;92:1038-49.

32. Alroughani R, Baskin R, Gold R, Tehrani-Shahrokh M, et al.Clinical Trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IMPPSG. Neurology. 2019;92:1038-49.

33. U.S. Food and Drug Administration. Ponvory prescribing information. 2020. Available at: www.accessdata.fda.gov/ drugsatfda_docs/label/2020/209999s000lbl.pdf (accessed 14 May 2022).

34. Merô G, Móser J, Liptai Z, et al. Effective therapy in highly active pediatric multiple sclerosis: Pharmacology, administration, and adverse effects. Ideggyogyaszati Szemle 2021;42(Suppl. 1):5–7.

35. Chitnis T, Tardieu M, Amato MP, et al. International Pediatric and Adult DMTs in POMS: Opportunities, challenges, and recommendations from the IMPPSG. Neurol Sci. 2021;42(Suppl. 1):15–8.

36. Waubant E, Barwick J, Korres G, et al. Interferon-beta-1a treatment in patients with relapsing-remitting multiple sclerosis: Pharmacology, administration, and adverse effects. Ideggyogyaszati Szemle 2021;42(Suppl. 1):19–23.

37. O’meara S, Weissbluth M, Pajonk F, et al. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with mapping multiple sclerosis (FOCUS). Pediatr Neurol. 2019;88:19–24.

38. Kappos R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1087–1098.

39. Sanfilippo I, Del Soldato D, Comi G, et al. Safety and efficacy of satralizumab (SA237) as add-on therapy to treat pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions. Ideggyogyaszati Szemle 2013;19:1261–7.